Prime Medicine says FDA clears IND for PM577a in Wilson disease trial - PRME News | RalliesPrime Medicine says FDA clears IND for PM577a in Wilson disease trial
P
PRME• FDA clears PM577a IND in Wilson disease
- Prime Medicine won FDA clearance of its IND for PM577a, an in vivo prime editor targeting H1069Q-mutated Wilson disease.
- The decision enables a global Phase 1/2 program with its previously cleared New Zealand CTA.
- Trial start is slated for H2 2026; initial clinical data are expected in 2027.
PROP
•
